• Myasthenia gravis

Vyvgart Generic Name & Formulations

General Description

Efgartigimod alfa-fcab 20mg/mL; soln for IV infusion after dilution; preservative-free.

Pharmacological Class

Neonatal Fc receptor blocker.

How Supplied

Single-dose vial (20mL)—1


Generic Availability


Vyvgart Indications


Generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive.

Vyvgart Dosage and Administration


Give by IV infusion over 60mins. 10mg/kg once weekly for 4 weeks. In patients weighing ≥120kg: 1200mg (3 vials) per infusion. Administer subsequent cycles based on clinical evaluation. Safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle: not established.


Not established.

Vyvgart Contraindications

Not Applicable

Vyvgart Boxed Warnings

Not Applicable

Vyvgart Warnings/Precautions


Increased risk of infection; monitor. Delay treatment in those with an active infection until resolved. If serious infection occurs, treat appropriately and consider withholding Vyvgart until resolved. Evaluate for age-appropriate vaccinations according to guidelines prior to initiation of a new treatment cycle. Monitor for hypersensitivity reactions during and for 1hr thereafter; discontinue if occurs. Moderate or severe renal impairment. Pregnancy. Nursing mothers.

Vyvgart Pharmacokinetics

See Literature

Vyvgart Interactions


Concomitant live or live-attenuated vaccines: not recommended. May antagonize immunoglobulin products, monoclonal antibodies, or antibody derivatives containing the human Fc domain of the IgG subclass; closely monitor for reduced effects; if concomitant long-term use is necessary, consider discontinuing Vyvgart and use alternatives.

Vyvgart Adverse Reactions

Adverse Reactions

Respiratory tract infection, headache, urinary tract infection, paresthesia, myalgia.

Vyvgart Clinical Trials

See Literature

Vyvgart Note

Not Applicable

Vyvgart Patient Counseling

See Literature